Mark I Furman

Summary

Affiliation: University of Massachusetts Medical School
Country: USA

Publications

  1. ncbi request reprint GPIIb/IIIa inhibitor-induced dethrombosis
    Mark I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Thromb Thrombolysis 18:11-7. 2004
  2. ncbi request reprint Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
    Mark I Furman
    Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 145:e6. 2003
  3. ncbi request reprint Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction
    M I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Worcester, Massachusetts 01655, USA
    J Am Coll Cardiol 38:1002-6. 2001
  4. ncbi request reprint Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective
    M I Furman
    Department of Medicine, University of Massachusetts Medical School, Worcester 01655, USA
    J Am Coll Cardiol 37:1571-80. 2001
  5. ncbi request reprint GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    M I Furman
    Cardiac Catheterization Laboratories, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Thromb Haemost 3:312-20. 2005
  6. ncbi request reprint Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE)
    Mark I Furman
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    Am Heart J 147:42-8. 2004
  7. doi request reprint Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I2-9. 2008
  8. doi request reprint Investigating the mechanisms of hyporesponse to antiplatelet approaches
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I21-7. 2008
  9. doi request reprint Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I28-35. 2008
  10. doi request reprint The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I17-20. 2008

Detail Information

Publications44

  1. ncbi request reprint GPIIb/IIIa inhibitor-induced dethrombosis
    Mark I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Thromb Thrombolysis 18:11-7. 2004
    ....
  2. ncbi request reprint Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
    Mark I Furman
    Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 145:e6. 2003
    ....
  3. ncbi request reprint Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction
    M I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Worcester, Massachusetts 01655, USA
    J Am Coll Cardiol 38:1002-6. 2001
    ..We investigated whether elevated levels of circulating monocyte-platelet aggregates (MPA) can be used to identify patients with acute myocardial infarction (AMI)...
  4. ncbi request reprint Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective
    M I Furman
    Department of Medicine, University of Massachusetts Medical School, Worcester 01655, USA
    J Am Coll Cardiol 37:1571-80. 2001
    ....
  5. ncbi request reprint GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    M I Furman
    Cardiac Catheterization Laboratories, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Thromb Haemost 3:312-20. 2005
    ....
  6. ncbi request reprint Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE)
    Mark I Furman
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    Am Heart J 147:42-8. 2004
    ..To examine the association between elevated leukocyte count and hospital mortality and heart failure in patients enrolled in the multinational, observational Global Registry of Acute Coronary Events (GRACE)...
  7. doi request reprint Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I2-9. 2008
    ..Currently, it appears that the use of GP IIb/IIIa antagonists might be most beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation myocardial infarction and elevated troponin levels...
  8. doi request reprint Investigating the mechanisms of hyporesponse to antiplatelet approaches
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I21-7. 2008
    ..Results from these studies could cause a paradigm shift toward individualized antiplatelet therapy, improving predictability of platelet inhibition, and diminishing the likelihood for hyporesponsiveness...
  9. doi request reprint Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I28-35. 2008
    ..Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences...
  10. doi request reprint The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I17-20. 2008
    ..Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation...
  11. ncbi request reprint Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance
    Andrew L Frelinger
    Center for Platelet Function Studies, Department of Pediatrics, UMass Memorial Medical Center, 55 Lake Ave N, Worcester, Massachusetts 01655, USA
    Circulation 113:2888-96. 2006
    ..Thrombotic events still occur in aspirin-treated patients with coronary artery disease...
  12. ncbi request reprint The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin
    Andrew L Frelinger
    Center for Platelet Function Studies, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Thromb Haemost 98:192-200. 2007
    ..This inhibition is enhanced in the presence other blood cells and calcium, but not aspirin...
  13. ncbi request reprint Application of flow cytometry to platelet disorders
    Matthew D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Semin Thromb Hemost 30:501-11. 2004
    ..Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care...
  14. ncbi request reprint Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization
    Mark I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    J Am Coll Cardiol 43:2319-25. 2004
    ....
  15. doi request reprint Whole blood analysis of leukocyte-platelet aggregates
    Marc R Barnard
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Curr Protoc Cytom . 2003
    ..Light scatter and at least one leukocyte-specific antibody are used to gate the desired population, and the presence of associated platelets is detected by immunostaining for abundant platelet-specific markers...
  16. doi request reprint Immunophenotypic analysis of platelets
    Lori A Krueger
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Curr Protoc Cytom . 2002
    ..Detailed discussion of appropriate sample handling, reagent preparation, flow cytometric set-up, and data interpretation are provided for three independent assays...
  17. ncbi request reprint Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation
    Andrew L Frelinger
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Am J Cardiol 92:1099-101. 2003
    ....
  18. ncbi request reprint Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
    M I Furman
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:352-8. 1998
    ..We sought to examine whether patients with stable coronary artery disease (CAD) have increased platelet reactivity and an enhanced propensity to form monocyte-platelet aggregates...
  19. doi request reprint Assessing the current role of platelet function testing
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I10-6. 2008
    ..The ideal platelet function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable...
  20. ncbi request reprint Current options in platelet function testing
    Alan D Michelson
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Department of Pediatrics and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Am J Cardiol 98:4N-10N. 2006
    ..In patients treated with antiplatelet drugs, the degree of platelet inhibition, as determined by several of these new platelet function assays, has been shown to predict major adverse cardiac events...
  21. ncbi request reprint Leukocytosis and adverse hospital outcomes after acute myocardial infarction
    Vandana Menon
    Department of Medicine, Division of Clinical Care Research, Tufts University School of Medicine New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 92:368-72. 2003
    ..These findings suggest that the WBC count should be considered an important prognostic factor associated with adverse hospital outcomes in patients with AMI...
  22. ncbi request reprint Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction
    A D Michelson
    Center for Platelet Function Studies, Departments of Pediatrics and Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Circulation 104:1533-7. 2001
    ..Platelet surface P-selectin is considered the "gold standard" marker of platelet activation. Degranulated, P-selectin-positive platelets, however, aggregate with leukocytes in vitro and rapidly lose surface P-selectin in vivo...
  23. ncbi request reprint Evaluation of platelet function by flow cytometry
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts, 01655, USA
    Methods 21:259-70. 2000
    ....
  24. ncbi request reprint 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection
    Chad E Darling
    Dept of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Avenue, North Worcester, MA, 01655, USA
    Basic Res Cardiol 102:274-8. 2007
    ..05), an outcome consistent with the concept that relief of sustained ischemia in a stuttered manner (analogous to postconditioning) may evoke cardioprotection in the clinical setting...
  25. ncbi request reprint The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin
    R Brannon Claytor
    Department of Surgery, Division of Vascular Surgery, and Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    J Vasc Surg 37:440-5. 2003
    ..We examined the effect of TR(1-41) on platelet activation and on platelet-endothelial cell adhesion...
  26. ncbi request reprint Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents
    M I Furman
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Curr Cardiol Rep 2:386-94. 2000
    ..Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems...
  27. ncbi request reprint The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities
    A L Frelinger
    Center for Platelet Function Studies, and Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 6:359-65. 2008
    ..We therefore examined whether R-138727 inhibits ADP- and collagen-triggered platelet procoagulant activities...
  28. ncbi request reprint Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 5:75-81. 2007
    ..Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. There is increasing interest in 'clopidogrel resistance'...
  29. ncbi request reprint Indices of platelet activation and the stability of coronary artery disease
    M D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 5:761-5. 2007
    ..To determine whether indices of platelet activation are associated with the stability of coronary artery disease (CAD)...
  30. ncbi request reprint Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity
    M R Barnard
    Center for Platelet Function Studies, University of Massachusettes Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 3:2563-70. 2005
    ..The aim of this study was to develop whole blood flow cytometry assays of these procoagulant activities and to investigate the effects of platelet binding to monocytes and neutrophils...
  31. ncbi request reprint Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion
    R B Claytor
    Department of Surgery, Division of Vascular Surgery, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Cytometry 43:308-13. 2001
    ..We report a novel method for in vitro detection of platelet-endothelial cell adhesion that allows endothelial cells to remain as an intact monolayer and for visualization of individual platelets...
  32. ncbi request reprint Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
    A L Frelinger
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Circulation 104:1374-9. 2001
    ..These apparently paradoxical results have been extensively referenced in the cardiology literature...
  33. ncbi request reprint Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction
    H L Dauerman
    Cardiovascular Division, University of Massachusetts Memorial Medical Center, Worcester 01655, USA
    Am J Cardiol 86:730-5. 2000
    ..The decrease in mortality occurs in the setting of broader use of reperfusion and adjunctive therapy (including primary angioplasty)...
  34. ncbi request reprint Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab
    M I Furman
    Center for Platelet Function Studies and the Division of Cardiovascular Medicine, Departments of Medicine, Pediatrics, and Cell Biology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 142:790-8. 2001
    ..Low-molecular-weight heparins have been reported to cause less platelet activation than unfractionated heparin...
  35. ncbi request reprint Laboratory markers of platelet activation and their clinical significance
    A D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Curr Opin Hematol 6:342-8. 1999
    ....
  36. ncbi request reprint GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood
    M I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, PA 01655, USA
    Thromb Haemost 84:492-8. 2000
    ..Fibrinogen binding to GPIIb-IIIa is important in the generation of platelet procoagulant activity...
  37. ncbi request reprint The role of platelet inhibition in the drug-eluting stent era
    Michael R Tamberella
    Department of Medicine and the Center for Platelet Function Studies, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA 01655, USA
    Coron Artery Dis 15:327-9. 2004
    ..Drug-eluting stents now account for greater than 50% of stenting procedures. This review focuses on the limited available data describing the use of antiplatelet agents in patients undergoing drug-eluting stent implantation...
  38. pmc The cleaved peptide of the thrombin receptor is a strong platelet agonist
    M I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical Center, Worcester, MA 01655, USA
    Proc Natl Acad Sci U S A 95:3082-7. 1998
    ..TR1-41-induced platelet activation was synergistic with TR42-55. In summary, the cleaved peptide of the seven-transmembrane domain TR (TR1-41) is a strong platelet agonist...
  39. ncbi request reprint Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention
    Harold L Dauerman
    Cardiac Unit, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    J Thromb Thrombolysis 13:127-32. 2002
    ..The impact of the short acting glycoprotein (GP) IIb-IIIa inhibitor, eptifibatide, on ACT measurements has not been studied...
  40. ncbi request reprint The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy
    Guy L Wheeler
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    Am Heart J 143:602-11. 2002
    ..Furthermore, a diminished degree of platelet inhibition is an independent predictor of adverse cardiac events, highlighting the need for accurate and precise monitoring of platelet function...
  41. ncbi request reprint An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates
    Stanley J Marciniak
    Centocor, Malvern, PA 19355, USA
    Thromb Haemost 87:1020-5. 2002
    ..The ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi. The present study examined the capacity of abciximab to reverse platelet aggregation in vitro...
  42. ncbi request reprint Measuring antiplatelet drug effects in the laboratory
    Paul Harrison
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, United Kingdom
    Thromb Res 120:323-36. 2007
    ..A clinically meaningful definition of "resistance" to antiplatelet drugs needs to be developed, based on data linking drug-dependent laboratory tests to clinical outcomes in patients...
  43. ncbi request reprint A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study
    David J Moliterno
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 42:1132-9. 2003
    ..Morrisville, North Carolina), a new point-of-care test...
  44. ncbi request reprint Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux
    Michael J Rohrer
    Division of Vascular Surgery and the Center for Platelet Function Studies, The University of Massachusetts Medical School, 55 Lake Avenue, North Worcester 01655, USA
    Cardiovasc Surg 10:464-9. 2002
    ..The purpose of this study was to determine whether patients with CVI maintain elevated levels of PMAs following complete surgical correction of chronic venous insufficiency...